Dose Escalation Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus

Completed · Phase 1 · Has a placebo group

Conditions studied: Systemic Lupus Erythematosus

In brief

A one month multi-dose study will evaluate the safety and tolerability of 3 intravenous infusions of RSLV-132 in subjects with inactive to mild SLE.

Key facts

Study ID

NCT02194400

Run by

Resolve Therapeutics

People needed

32

Starts

2014-07-01

Expected to finish

2015-11-01

Last updated by the study team

2015-12-09

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Stable SLE with no anticipated change in medications for the next 60 days

You may not qualify if…

• Other biologic drugs

Where it is running

• Clinical Research of West Florida — Clearwater, Florida, United States
• West Michigan Rheumatology — Grand Rapids, Michigan, United States
• Altoona Center for Clinical Research — Duncansville, Pennsylvania, United States
• Metroplex Clinical Research — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.